Saturday, July 21, 2012

FDA approves Cipher’s Absorica to treat severe recalcitrant nodular acne

FDA approves Cipher’s Absorica to treat severe recalcitrant nodular acne: Cipher Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, Cipher's novel, patented brand formulation of the acne medication isotretinoin (left structure), for the treatment of severe recalcitrant nodular acne.

No comments:

Post a Comment